Nexalin Technology, Inc. — Director's Dealing 2025

Feb 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nexalin Technology, Inc. (NXL)
CIK: 0001527352
Period of Report: 2025-02-26

Reporting Person: Owens David (Director, Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-26	Stock Option (right to buy)	$0.894	A	139821	Acquired	2033-06-30	Common Stock (139821)	Direct
2025-02-26	Stock Option (right to buy)	$0.894	A	654363	Acquired	2034-06-30	Common Stock (654363)	Direct
2025-02-26	Stock Option (right to buy)	$2.95	A	125000	Acquired	2029-12-27	Common Stock (125000)	Direct

Footnotes

F1: The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares.